Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENAVO-AF: Enavogliflozin to Prevent Atrial Fibrillation Recurrence After Catheter Ablation in Heart Failure
KCT0010074Phase 4Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of enavogliflozin in Atrial fibrillation (AFib), heart failure (HF), sponsored by Daewoong Pharmaceutical. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
enavogliflozin
03
Conditions
Atrial fibrillation (AFib)heart failure (HF)
Beyond the preview
Go deeper on KCT0010074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010074.